Angina (Angina Pectoris) - Pipeline Review, H2 2015 Summary Global Markets Directs, Angina (Angina Pectoris) - Pipeline Review, H2 2015, provides an overview of the Angina (Angina Pectoris)s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Angina (Angina Pectoris) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Angina (Angina Pectoris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Angina (Angina Pectoris) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Angina (Angina Pectoris) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Angina (Angina Pectoris) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Angina (Angina Pectoris) Overview 8 Therapeutics Development 9 Pipeline Products for Angina (Angina Pectoris) - Overview 9 Angina (Angina Pectoris) - Therapeutics under Development by Companies 10 Angina (Angina Pectoris) - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Angina (Angina Pectoris) - Products under Development by Companies 14 Angina (Angina Pectoris) - Companies Involved in Therapeutics Development 15 Baxalta Incorporated 15 Bayer AG 16 Cardiolynx AG 17 Gilead Sciences, Inc. 18 Juventas Therapeutics, Inc. 19 Kuhnil Pharmaceutical Co., Ltd. 20 Lacer, S.A. 21 Lee's Pharmaceutical Holdings Limited 22 LegoChem Biosciences, Inc 23 Milestone Pharmaceuticals, Inc. 24 Taxus Cardium Pharmaceuticals Group Inc. 25 ViroMed Co., Ltd. 26 Angina (Angina Pectoris) - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 aladorian sodium - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 alferminogene tadenovec - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 BAY-606583 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CLC-1201 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 CLC-1280 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 eleclazine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 JVS-100 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 KI-1007 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 LA-419 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 LA-8045 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 MSP-2017 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecule to Activate Soluble Guanylate Cyclase for Angina Pectoris - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 VM-202 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 ZK-001 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Angina (Angina Pectoris) - Recent Pipeline Updates 59 Angina (Angina Pectoris) - Dormant Projects 68 Angina (Angina Pectoris) - Discontinued Products 70 Angina (Angina Pectoris) - Product Development Milestones 71 Featured News & Press Releases 71 Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 71 Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted' 73 May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 74 May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 75 Nov 19, 2012: Cardium Therapeutics Announces Patent Award for Rights to Cardiovascular Gene Therapy For Treatment Of Heart Disease 76 Sep 20, 2012: Cardiolynx Receives Patent For Improved Angina Pectoris Drug CLC-1280 78 Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients 79 Apr 18, 2011: Lees Pharma Completes Phase I Study Of Anti-Platelet Drug Declotana 80 Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 80 Oct 23, 2007: Announcement of supplemental approval of indication of Sigmart Injection, a treatment drug for unstable angina pectoris 80 Appendix 82 Methodology 82 Coverage 82 Secondary Research 82 Primary Research 82 Expert Panel Validation 82 Contact Us 82 Disclaimer 83
List of Tables Number of Products under Development for Angina (Angina Pectoris), H2 2015 9 Number of Products under Development by Companies, H2 2015 10 Comparative Analysis by Late Stage Development, H2 2015 11 Comparative Analysis by Clinical Stage Development, H2 2015 12 Comparative Analysis by Early Stage Development, H2 2015 13 Products under Development by Companies, H2 2015 14 Angina (Angina Pectoris) - Pipeline by Baxalta Incorporated, H2 2015 15 Angina (Angina Pectoris) - Pipeline by Bayer AG, H2 2015 16 Angina (Angina Pectoris) - Pipeline by Cardiolynx AG, H2 2015 17 Angina (Angina Pectoris) - Pipeline by Gilead Sciences, Inc., H2 2015 18 Angina (Angina Pectoris) - Pipeline by Juventas Therapeutics, Inc., H2 2015 19 Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2015 20 Angina (Angina Pectoris) - Pipeline by Lacer, S.A., H2 2015 21 Angina (Angina Pectoris) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 22 Angina (Angina Pectoris) - Pipeline by LegoChem Biosciences, Inc, H2 2015 23 Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals, Inc., H2 2015 24 Angina (Angina Pectoris) - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2015 25 Angina (Angina Pectoris) - Pipeline by ViroMed Co., Ltd., H2 2015 26 Assessment by Monotherapy Products, H2 2015 27 Number of Products by Stage and Target, H2 2015 29 Number of Products by Stage and Mechanism of Action, H2 2015 31 Number of Products by Stage and Route of Administration, H2 2015 33 Number of Products by Stage and Molecule Type, H2 2015 35 Angina (Angina Pectoris) Therapeutics - Recent Pipeline Updates, H2 2015 59 Angina (Angina Pectoris) - Dormant Projects, H2 2015 68 Angina (Angina Pectoris) - Dormant Projects (Contd..1), H2 2015 69 Angina (Angina Pectoris) - Discontinued Products, H2 2015 70
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.